G. Hasbal Çelikok Et Al. , "Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment," Oncology Letters , vol.21, no.3, pp.209-218, 2021
Hasbal Çelikok, G. Et Al. 2021. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. Oncology Letters , vol.21, no.3 , 209-218.
Hasbal Çelikok, G., Aksoy Sağırlı, P., Altıparmak Ülbegi, G., & Can, A., (2021). Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. Oncology Letters , vol.21, no.3, 209-218.
Hasbal Çelikok, Gözde Et Al. "Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment," Oncology Letters , vol.21, no.3, 209-218, 2021
Hasbal Çelikok, Gözde H. Et Al. "Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment." Oncology Letters , vol.21, no.3, pp.209-218, 2021
Hasbal Çelikok, G. Et Al. (2021) . "Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment." Oncology Letters , vol.21, no.3, pp.209-218.
@article{article, author={Gözde Hasbal Çelikok Et Al. }, title={Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment}, journal={Oncology Letters}, year=2021, pages={209-218} }